Dermata Therapeutics (NASDAQ:DRMA) versus Niagen Bioscience (NASDAQ:NAGE) Head-To-Head Contrast

Niagen Bioscience (NASDAQ:NAGE) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Niagen Bioscience and Dermata Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0	1	3	1	3.00
Dermata Therapeutics	1	0	0	0	1.00

Niagen Bioscience presently has a consensus target price of $10.33, indicating a potential upside of 221.91%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Niagen Bioscience is more favorable than Dermata Therapeutics.

Volatility and Risk

Niagen Bioscience has a beta of 2.09, indicating that its share price is 109% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Earnings and Valuation

This table compares Niagen Bioscience and Dermata Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42 million	1.98	$17.38 million	$0.18	17.83
Dermata Therapeutics	N/A	N/A	-$7.56 million	($4.39)	-0.32

Niagen Bioscience has higher revenue and earnings than Dermata Therapeutics. Dermata Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Niagen Bioscience and Dermata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	12.39%	17.95%	13.17%
Dermata Therapeutics	N/A	-166.66%	-130.13%

Insider and Institutional Ownership

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 21.9% of Dermata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Niagen Bioscience beats Dermata Therapeutics on 13 of the 14 factors compared between the two stocks.

About Niagen Bioscience

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.